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Background: Subclinical cardiac dysfunction has been associated with increased mortality, and heart
failure increases the risk of sudden cardiac death (SCD). Less well known is whether subclinical cardiac
dysfunction is also a risk factor for SCD. Our objective was to assess the association between echocardio-
graphic parameters and SCD in a community-dwelling population free of heart failure.
Methods and Results: We computed hazard ratios (HRs) for left atrium diameter, left ventricular (LV)
end-diastolic dimension, LV end-systolic dimension, LV mass, qualitative LV systolic function, LV
fractional shortening, and diastolic function. During a median follow-up of 6.3 years in 4,686 participants,
68 participants died because of SCD. Significant associations with SCD were observed for qualitative LV
systolic function and LV fractional shortening. For moderate/poor qualitative LV systolic function, the HR
for SCD was 2.54 (95% confidence interval [CI] 1.10e5.87). Each standard deviation decrease in LV
fractional shortening was associated with an HR of 1.36 (95% CI 1.09e1.70).
Conclusions: Subclinical abnormalities in LV systolic function were associated with SCD risk in this
general population. Although prediction of SCD remains difficult and traditional cardiovascular risk
factors are of greatest importance, this knowledge might guide future directions to prevent SCD in persons
with subclinical cardiac dysfunction. (J Cardiac Fail 2016;22:17e23)
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18 Journal of Cardiac Failure Vol. 22 No. 1 January 2016clinically evident, subclinical cardiac dysfunction is often
present4 with an increased risk of morbidity and mortal-
ity.5,6 Impaired LV function, as reflected by hypertrophy
and impaired ejection fraction, has previously been demon-
strated to be associated with an increased incidence of SCD
in high-risk populations, eg, athletes,7 patients with hyper-
trophic cardiomyopathy,8 and patients with coronary heart
disease (CHD).9 However, because almost all studies are
performed in high-risk patient populations, population-
based data are limited. Therefore, the objective of the
present study was to investigate the association between
subclinical abnormalities in echocardiographic parameters
and the occurrence of SCD in a general population of older
adults free of heart failure.Methods
Setting
The Rotterdam Study is a prospective population-based cohort
study that started in 1990 in the city of Rotterdam, the
Netherlands. Details have been described elsewhere.10 In short,
all inhabitants of the Ommoord district aged $55 years were
invited to participate. At baseline (1990e1993) 7,983 participants
(response rate 78%) were enrolled. In 2000, an additional 3,011
participants were enrolled (response rate 67%). Follow-up exami-
nations are conducted every 4e5 years and consist of a home
interview and an extensive set of tests at a research facility. Partic-
ipants are continuously and actively monitored for major
morbidity and mortality through access to general practitioners
and municipality records. The Rotterdam Study was approved
by the Medical Ethics Committee according to the Wet Bevolking-
sonderzoek ERGO (Population Study Act Rotterdam Study)
executed by the Ministry of Health, Welfare, and Sport of the
Netherlands. All participants provided written informed consent.
Study Population
Echocardiographic measurements were obtained in 2002e2005
during the 4th examination of the 1st cohort and the 2nd examina-
tion of the 2nd cohort. We excluded participants with poor-quality
echocardiograms and with a history of heart failure. Heart failure
diagnosis was adjudicated in accordance with the guidelines of the
European Society of Cardiology and included typical signs or
symptoms of heart failure confirmed by objective evidence of car-
diac dysfunction.11 Adjudication of heart failure diagnosis was
done without knowledge of the echocardiography results.
Outcome Definition
SCD was adjudicated according to the Myerburg definition
endorsed by the European Society of Cardiology: ‘‘a natural death
due to cardiac causes, heralded by abrupt loss of consciousness
within 1 hour from onset of acute symptoms; preexisting heart dis-
ease may have been known to be present, but the time and mode of
death are unexpected.’’12 Identification and validation of SCD
cases was done independently by 2 research physicians and subse-
quently confirmed by an experienced cardiologist after reviewing
the medical files as described in more detail previously.13 Follow-
up was complete for almost all deaths (96%) up to January
1, 2011.Echocardiographic Measurements
Resting transthoracic echocardiograms were obtained by certi-
fied experienced echocardiographers according to a standardized
protocol as described in detail previously.14 In short, left atrium
(LA) diameter, LV end-diastolic dimension (LVEDD), and LV
end-systolic dimension (LVESD) were measured in the parasternal
long-axis view with the use of M-mode with 2-dimensional guid-
ance. LV mass in grams was calculated as 0.80 (1.04  (intraven-
tricular septum thickness þ LVEDD þ posterior wall thickness)3
 (LVEDD3)) þ 0.6.15 LV fractional shortening at the endocar-
dium was calculated as (LVEDD  LVESD)/LVEDD 
100%.16 Global qualitative LV systolic function was assessed by
means of subjective visual grading, in 4 established categories
(normal, fair, moderate, or poor) from the 2-dimensional echocar-
diogram. The E/A ratio was assessed with the use of pulsed
Doppler recordings of transmittal filling velocity in the apical
4-chamber view, with the sample volume placed in the mitral
valve orifice near the tips of the leaflets. Doppler peak E and
peak A velocities were averaged over 3 cycles. E/A ratio was
computed by dividing Doppler peak E velocity by Doppler peak
A velocity.17 Mitral valve inflow deceleration time (MVDT) was
measured as the time between the peak E-wave and the upper
deceleration slope extrapolated to the zero baseline. LVEDD, frac-
tional shortening, LV mass, and LA diameter were categorized
into 4 categoriesdnormal, fair, moderate, and poordbased on
guideline-derived reference values,18 but because of the small
number of participants in the moderate and poor categories, those
were combined in the analyses. LVESD was categorized into 2
categories: normal and abnormal.18,19 Diastolic function was
defined into 3 categoriesdnormal, impaired relaxation, and a
restrictive pattern18,19dwith the use of E/A ratio and MVDT.4,20
Because we did not measure the early diastolic longitudinal veloc-
ity of the mitral annulus, we could not categorize all participants
in these diastolic function categories and classified those that we
could not as indeterminate.14 Reference values for the categoriza-
tion are presented in Table 1, separately for men and women when
appropriate.18e21 Intrareader and interreader reproducibility mea-
surements have been described by Kardys et al.14
Potential Covariables
Body mass index was calculated as weight in kilograms divided
by height in squared meters. Systolic and diastolic blood pressures
were measured in sitting position at the right upper arm. The
average of 2 consecutive measurements was taken. Hypertension
was defined as systolic blood pressure O140 mm Hg, diastolic
blood pressure O90 mm Hg, or use of blood pressureelowering
medication for the indication hypertension. Total and high-
density lipoprotein cholesterol were measured with the use of
standardized laboratory techniques. Diabetes mellitus was defined
as fasting glucose O6.9 mmol/L, nonfasting glucose O11.0
mmol/L, use of blood glucoseelowering medication, or a previous
diagnosis of diabetes mellitus. A history of CHD was defined as a
myocardial infarction or coronary revascularization procedure.11
Smoking status was assessed during the interview. Heart ratee
corrected QT (QTc) interval according to the Bazett formula
was derived from standard resting electrocardiograms.
Data Analysis
We used Cox proportional hazards models to analyze the asso-
ciation between multiple echocardiographic parameters and SCD
Table 1. Reference Values, Separated for Men and Women When Appropriate, and Number of Participants for Categories of
Echocardiographic Parameters
Echocardiographic
Parameter Sex Normal Fair Moderate* Poor* Missing
LVEDD (mm) Men 42e59 60e63 64e68 $69
Women 39e53 54e57 58e61 $62
n 3,935 (84%) 554 (12%) 153 (3%) 37 (!1%) 7 (!1%)
Fractional shortening (%) Men 25e43 20e24 15e19 #14
Women 27e45 22e26 17e21 #16
n 4,439 (95%) 164 (4%) 42 (!1%) 23 (!1%) 18 (!1%)
LV mass (g) Men 88e224 225e258 259e292 $293
Women 67e162 163e186 187e210 $211
n 4,062 (87%) 316 (7%) 153 (3%) 99 (2%) 56 (1%)
LA diameter (mm) Men #40 41e46 47e52 $53
Women #38 39e42 43e46 $47
n 2,148 (46%) 1,442 (31%) 746 (16%) 339 (7%) 11 (!1%)
Qualitative LV systolic
function
n 2,734 (58%) 1,701 (36%) 180 (4%) 63 (1%) 8 (!1%)
Normal Abnormal
LVESD (mm) All !45 $45
n 4,546 (97%) 122 (3%) 18 (!1%)
Normal Impaired Relaxation Restrictive Pattern Indeterminate
Diastolic function All E/A 0.75e1.50 &
MVDT 150e280
E/A !0.75 &
MVDT !150
E/A O1.50 &
MVDTO280
Other combinations
n 2,726 (58%) 207 (4%) 18 (!1%) 1,494 (32%) 241 (5%)
LVEDD, LV end-diastolic dimension; LV, left ventricular; LA, left atrial; LVESD, LV end-systolic dimension; MVDT, mitral valve inflow deceleration-
time.
Due to rounding percentages do not always exactly add up to 100%.
*Because of the small number of participants, the moderate and poor categories were combined in the analyses.
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cardiography until date of death, loss to follow-up (n 5 11), or
the end of the study period (January 1, 2011). Echocardiographic
measurements were analyzed both continuously and categorically.
For the continuous analysis, we analyzed per sex-specific age-
adjusted standard deviation (SD), derived through linear regres-
sion by saving standardized residuals. Sex and age at date of
echocardiography were included as covariables in the basic model
for the analysis of categories. The covariables in the multivariable
model were selected by means of backward selection with the use
of the likelihood ratio test with a cutoff P value of 0.1. We also
used QT and RR intervals in our model instead of QTc, to inves-
tigate whether there is residual confounding by heart rate, as is
known for the Bazett formula. We constructed cumulative sur-
vival curves for categorized echocardiographic parameters.
Because we were interested in cause-specific hazard ratios
(HRs), we used traditional Cox models that censor participants
at the time of death from causes other than SCD.22 Nevertheless,
we performed sensitivity analyses on the categoric echocardio-
graphic parameters by means of the data augmentation method
and unstratified model described by Lunn and McNeil to estimate
the HR of SCD compared with non-SCD in the multivariable
model to account for competing risk of deaths from other
causes.23 We repeated all analyses after exclusion of persons
with a history of CHD and persons with moderate or poor values
of the systolic parameters (LVEDD, LVESD, fractional short-
ening, and qualitative LV systolic function). We also analyzed
the association while censoring persons with incident CHD dur-
ing follow-up. We combined significantly associated parameters
into different models for which we assessed discriminative ability
by internally validated (ie, optimism-corrected) concordance
statistic (c-statistic).A 2-sided P value of !0.05 was considered to be statistically
significant. All measures of association are presented as HR
with 95% confidence intervals (CIs). We used IBM SPSS Statistics
version 21.0 (IBM Corp, Somers, New York), R Statistical Soft-
ware (Foundation for Statistical Computing, Vienna, Austria),
and SAS version 9.3 (SAS Institute, Cary, North Carolina).Results
General Characteristics
A total of 4,686 participants were eligible for analysis
(Fig. 1). Their baseline characteristics are presented in
Table 2. The total study population comprised 2,737
women (58%) and the overall mean age of the participants
was 71.8 years.
During a median follow-up of 6.3 years (interquartile
range 1.4) 68 of a total of 804 deaths were attributed to
SCD. All multivariable models were adjusted for systolic
and diastolic blood pressures, diabetes mellitus, smoking,
CHD, and QTc interval. Other covariables did not
contribute to the model. Using QT and RR intervals instead
of QTc did not affect the results.
Continuous Analysis
Results for the analysis on echocardiographic parame-
ters, analyzed per sex-specific, age-adjusted SD increase
or decrease are presented in Table 3. Per 1 SD decrease
in fractional shortening, the risk of SCD increased (HR
1.36, 95% CI 1.09e1.70). Increase of LVEDD, LVESD,
Fig. 1. Selection of the study population.
Table 2. Baseline Characteristics of the Population for
Analysis (2002e2005; n 5 4,686)
Characteristic
Total Population,
N 5 4,686
Age (y) 71.8 6 7.4
Sex
Men 1,949 (41.6%)
Women 2,737 (58.4%)
Body mass index (kg/m2) 27.4 6 3.9
Blood pressure (mm Hg)
Systolic 150 6 21
Diastolic 80 6 11
Hypertension 3,760 (80.2%)
Total cholesterol (mmol/L) 5.7 6 2.1
High-density lipoprotein cholesterol (mmol/L) 1.5 6 2.0
Diabetes mellitus 685 (14.6%)
Current smoking 716 (15.3%)
Heart rate (beats/min) 69 6 11
History of coronary heart disease 387 (8.3%)
History of myocardial infarction 267 (5.7%)*
History of revascularization 247 (5.3%)*
Atrial fibrillation 224 (4.8%)
Atrioventricular block 239 (5.1%)
Heart-rate corrected QT-interval (ms) 433 6 26
Data are presented as mean 6 SD or n (%).
*Numbers overlap.
20 Journal of Cardiac Failure Vol. 22 No. 1 January 2016LV mass, and LA diameter were not significantly associated
with a higher risk of SCD.
Categoric Analysis
The number of participants for each category of the
echocardiographic parameters are presented in Table 1.
The risk of SCD increased with deteriorating cardiac func-
tion in the age- and sex-adjusted model (Supplemental
Fig. 1). In the multivariable model, the risk of SCD was
higher only in the moderate/poor qualitative LV systolic
function category (HR 2.54, 95% CI 1.10e5.87) compared
with normal (Table 4). An abnormal LVESD (HR 1.42,
95% CI 0.55e3.65) did not significantly affect the risk of
SCD. Diastolic function, as measured by the E/A ratio
and MVDT, did not reach statistical significance (impaired
relaxation: HR 1.22, 95% CI 0.46e3.25; restrictive pattern:
HR 5.59, 95% CI 0.72e43.51; indeterminate: HR 0.70,
95% CI 0.38e1.30). Analyzed separately, E/A ratio and
MVDT also provided nonsignificant results. Results from
the sex-stratified analyses and sensitivity analyses by exclu-
sion of persons with CHD were consistent with the results
in the overall population (data not shown), but the number
of SCD cases limited our ability to draw firm conclusions.The results of the competing risk model are presented in
Supplemental Table 1. Higher LV mass, LA diameter, and
qualitative LV systolic function were significantly associ-
ated with non-SCD.
Continuous Analysis in Persons with Normal and Fair
Systolic Function
After exclusion of 677 participants with a moderate
or poor value on any of the systolic parameters (Fig. 1; re-
maining SCDs: n5 49), only the effects of fractional short-
ening and LVEDD were statistically significant. Greater
LVEDD was protective from SCD (HR 0.76, 95% CI
0.59e0.99). Per SD decrease in fractional shortening the
HR was 1.32 (95% CI 1.01e1.73) in the adjusted model.
An analysis while censoring persons with incident CHD,
showed similar HRs, although not significant owing to the
low number of cases (data not shown).
Discrimination Analysis in Persons with Normal and
Fair Systolic Function
The addition of fractional shortening (the most consis-
tently associated parameter) yielded a small increase in
c-statistic when added to a model of the other covariables
that are known to be associated with SCD: 0.78 (95% CI
0.71e0.86) for the model with known covariables; 0.79
(95% CI 0.72e0.87) after addition of fractional shortening.
Discussion
We demonstrated that subclinical abnormalities in LV
systolic function are associated with an increased risk of
SCD in the general population. However, the increase in
discriminative value, when added to a model with well
known clinical risk factors, is limited.
Table 3. Continuous Echocardiographic Parameters and Sudden Cardiac Death Risk
Echocardiographic Measurement
Mean 6 SD Model 1 Model 2
Men Women HR (95% CI) P Value HR (95% CI) P Value
LVEDD* 53 6 5 49 6 5 1.05 (0.83e1.33) .68 0.91 (0.72e1.14) .41
LVESD* 34 6 6 30 6 5 1.41 (1.17e1.69) !.001 1.13 (0.93e1.39) .23
Fractional shorteningy 37 6 7 40 6 6 1.66 (1.35e2.03) !.001 1.36 (1.09e1.70) .006
LV mass* 162 6 45 131 6 35 1.15 (0.92e1.43) .23 0.96 (0.76e1.22) .75
LA diameter* 42 6 6 39 6 5 1.07 (0.84e1.36) .58 0.94 (0.73e1.20) .60
HR, hazard ratio; CI, confidence interval; other abbreviations as in Table 1.
Model 1: crude model. Model 2: adjusted for systolic blood pressure, diastolic blood pressure, diabetes mellitus, current smoking, history of coronary heart
disease, and heart-rate corrected QT-interval.
*Analyzed continuously, HRs per sex-specific age-adjusted SD increase.
yAnalyzed continuously, HRs per sex-specific age-adjusted SD decrease.
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eral population, showing that a lower fractional shortening
in 802 men aged 42e60 years was associated with an
increased risk of SCD.24 Our study adds to this knowledge
because it was performed in a somewhat older population
comprising both sexes.
There are several pathways through which a decreased
LV systolic function can increase the risk of SCD. First, a
low-normal fractional shortening could indicate progres-
sion toward a subclinical stage of heart failure. It has previ-
ously been shown that ventricular dysfunction is often
present before heart failure becomes clinically evident4
and gives rise to increased morbidity and mortality.5,6
Alternatively, low-normal fractional shortening and SCD
could have a shared etiology, such as hypertension, CHD,
or genetic variations. Systolic dysfunction is primarily
caused by CHD,19 which is also an important risk factor
for SCD.25 However, after adjustment for a history of
CHD in our analysis or exclusion of persons with manifest
CHD, the association between fractional shortening and
SCD remained statistically significant. Large-scale genetic
studies identified genetic variations associated with QT
and RR intervals, both well recognized SCD risk factors,
which were annotated within genes associated with mende-
lian disorders resulting in heart failure.26e29
Earlier studies showed that in patients with CHD, LV
mass predicted SCD,30 and studies in athletes demonstratedTable 4. Categoric Echocardiographic Param
Echocardiographic
Measurement
Model 1
Fair Moderate/Poo
HR (95% CI) P Value HR (95% CI) P
LVEDD 1.03 (0.47e2.27) .94 2.42 (1.04e5.63)
Fractional shortening 2.10 (0.90e4.90) .08 5.42 (2.17e13.55)
Qualitative LV
systolic function
1.57 (0.90e2.74) .11 4.16 (2.05e8.43)
LV mass 1.95 (0.92e4.15) .08 1.66 (0.70e3.92)
LA diameter 1.33 (0.76e2.34) .32 1.25 (0.67e2.32)
Normal is the reference category. For sex-specific categorization of the LVecho
Model 2: adjusted for age, sex, systolic blood pressure, diastolic blood pressure,
heart-rate corrected QT-interval. Abbreviations as in Tables 1 and 3.a higher proportion of persons with an ‘‘athlete’s heart’’31
among the SCD cases. This leads to the hypothesis that
SCD has a different origin in persons with CHD, athletes,
and the general population, where SCD has a heteroge-
neous pathoetiology.30
The high level of completeness of follow-up in the pre-
sent cohort is an important asset. We had access to very
detailed information on morbidity and mortality events
through direct access to the medical records. Besides that,
data are collected within the Rotterdam Study according
to standardized protocols. Because the Rotterdam Study
has no exclusion criteria for enrollment, our results are
generalizable to the general population.
This study has some limitations we should address. First
is the heterogeneity of SCD cases which follows from the
definition of SCD. However, this definition has been widely
endorsed for several years and is in accordance with formal
cardiologic guidelines. The incidence rate in our study was
similar to other studies,1,13 indicating adequate case valida-
tion. Second, the echocardiographic data we had did not
enable us to determine LV volumes and thereby LVejection
fraction. However, fractional shortening and ejection frac-
tion are highly correlated. Furthermore, assessment of dia-
stolic function in our study was complicated by the fact that
we did not measure the early diastolic longitudinal velocity
of the mitral annulus. Finally, because we had a limited
number of cases, we could include only a limitedeters and Sudden Cardiac Death Risk
Model 2
r Fair Moderate/Poor
Value HR (95% CI) P Value HR (95% CI) P Value
.04 0.93 (0.42e2.07) .86 1.60 (0.66e3.91) .30
!.001 1.66 (0.70e3.95) .25 2.48 (0.89e6.93) .08
!.001 1.38 (0.77e2.50) .28 2.54 (1.10e5.87) .030
.25 1.49 (0.67e3.32) .33 1.14 (0.44e2.94) .78
.48 1.37 (0.76e2.44) .29 0.98 (0.51e1.91) .96
cardiographic parameter refer to Table 1. Model 1: adjusted for age and sex.
diabetes mellitus, current smoking, history of coronary heart disease, and
22 Journal of Cardiac Failure Vol. 22 No. 1 January 2016number of confounders. But because we adjusted for the
most important confounders, we expect minimal residual
confounding.
In conclusion, in this general population, subclinical
abnormalities in LV systolic function were associated
with an increased risk of SCD. Because the discriminative
ability of fractional shortening was limited, prediction re-
mains difficult and established clinical factors are most
important. However, our findings might lead to a better
understanding of the negative outcomes associated with
subclinical (stage B) heart failure and the pathophysiology
of SCD and might guide future directions to prevent SCD in
persons with subclinical cardiac dysfunction.
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